A Newly Discovered Antibody Neutralizes Many Variants By Locking The Receptor-Binding Domain In A Closed Position

As SARS-CoV-2 variants grow in type and frequency, Covid-19 researchers are on the hunt for parts of the virus that remain consistent across variants in order to create Covid-19 treatments that work for multiple strains of the virus. This is the fourth in a series discussing these potential Achilles’ heels for Covid-19. Read more from this series in parts one, two, and three.

Cocktails of monoclonal antibodies are valuable therapies for the prevention and treatment of Covid-19.  However, their utility has been compromised by variants of SARS-CoV-2 that evade one or more of the antibodies in the mix. 

A new paper by Scheid et al. describes a new monoclonal antibody—BG10-19—that has a valuable set of characteristics. It is highly potent and active against a broad range of variants. BG10-19 and other antibodies analyzed in the study bind to the receptor-binding domain of the spike protein. The receptor-binding domain can be either open or closed. It must be in the open configuration to bind the ACE2 receptor to initiate infection.

Read the full article on Forbes.

© William A. Haseltine, PhD. All Rights Reserved.